louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04387370: The Use of the Hem-o-lok Clip in Appendectomy: Single or Double?
Official title: Comparison of Single and Double Hem-o-log Clips in Laparoscopic Appendectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Appendicitis
Keywords: Laparoscopic appendectomy
Hem-o-lok clip
stump closure
Lead sponsor: Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2020-05-13
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients operated on for acute appendicitis

Brief summary: Stump safety is provided by different methods in laparoscopic appendectomy. Stapler use, binding with endoloop and nonabsorbable clip are the most common methods. Although the stapler is safe, it creates a significant cost increase. In connecting with the endoloop, the learning curve and surgical time are longer. Nonabsorbable clip application which has been used recently; Urethra was also used in appendectomy after its safety has been proven by large studies to close cystic ducts and vascular structures. Its advantages such as low cost, no need for a learning curve and shortening the surgical time have increased the frequency of use.In this prospective observational study; It will be aimed to investigate the effects of stump closure methods applied in laparoscopic appendectomy on short-term clinical results. In addition, the factors that determine the surgeon's stump closure method and cost results will be tried to be determined.

Detailed description: Detailed explanation will be made later if necessary.

Eligibility criteria: Inclusion Criteria

* diagnosis of acute appendicitis
* Performing laparoscopic surgery
* Patients with an ASA score of I-II-III

Exclusion Criteria:

* Appendectomies with the patient's refusal to participate in the study
* Open surgery
* Primary pathology without appendicitis

Primary outcomes:
measure: Is it safe to close the appendix stump with a single hem-o-lok clip?
timeFrame: one year
Secondary outcomes:
measure: The effect of single and double hem-o-lok clips on cost in laparoscopic appendectomy
timeFrame: one week
Other outcomes:
Locations:
city: Diyarbakır
country: Turkey
facility: Dicle University Medical of School, Department of Gastrointestinal Surgery
Study officials:
affiliation: Dicle University Medical of School
name: Abdullah Oğuz, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dicle University Medical of School
name: Ulaş Aday, MD
role: STUDY_CHAIR
affiliation: Dicle University Medical of School
name: Mehmet veysi Bahadır, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00266370: A Pathology Reference Laboratory for the Study of Infectious Diseases and Malignant Lymphoma
Official title: A Pathology Reference Laboratory for the Study of Infectious Diseases and Malignant Lymphoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lymphoma
Lead sponsor: National Health Research Institutes, Taiwan
Sponsor class: OTHER
First posted: 2005-12-16
Enrollment: 100
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: OTHER

Brief summary: 1. To establish a pathology reference laboratory for the consultation on the diagnosis of infectious diseases and lymphoma.
2. To study the specific pathogens on 100 cases of unexplained death due to infectious diseases in the files of Taiwan CDC and the Forensic Institutes of Department of Law and Justice.
3. To study the distribution of children lymphoid lesions in Vietnam and Taiwan and their virus association.
4. To establish a tissue bank for infectious diseases and lymphoma.


Eligibility criteria: Inclusion Criteria:

Clinical diagnosis of infectious diseases and lymphoma.

Exclusion Criteria:

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zhunan Town, Miaoli County
country: Taiwan
facility: National Health Research Institutes
Study officials:
affiliation: Division of Clinical Research, National Health Research Institutes
name: Ih-Jen Su, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06311370: Acceptability, Feasibility, and Development of an AI Driven, Multi-sensor, Non-invasive Digital Mental Health Platform in Children With ADHD and Emotional Symptoms
Official title: Acceptability, Feasibility, and Development of an AI Driven, Multi-sensor, Non-invasive Digital Mental Health Platform in Children With ADHD and Emotional Symptoms
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: ADHD
Autism
Lead sponsor: MaxisHealth
Sponsor class: INDUSTRY
First posted: 2024-03-15
Enrollment: 10
Sex: ALL
Minimum age (years): 4
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children with ADHD attending the therapeutic school.

Brief summary: This is an observational study collecting data using a wearable to measure the biometric features in youth with Attention deficit hyperactivity disorder(ADHD) and Autism.

Detailed description: Participants in therapeutic school for disruptive behavior with Attention deficit hyperactivity disorder( ADHD), Autism with age 4-7 year old. Participant will wear watch during their school days for 5 days in presence of investigator and raters taking behavioral observation. The data collected from the raters and wearable will be analyzed to correlate emotional dysregulation.

Eligibility criteria: Inclusion Criteria:

* Children in the therapeutic school, diagnosed with ADHD

Exclusion Criteria:

* Unable to tolerate wearing the watch

Primary outcomes:
measure: Emotion dysregulation
timeFrame: 20 hours upto 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Brooklyn
country: United States
facility: The League School
state: New York
Study officials:
References:
Clinical trial NCT04140370: Frailty Prevalence in Surgical European Patients. European Prospective Cohort Stufy of the Prevalence of Frailty in Surgical Patients.
Official title: Frailty Prevalence in Surgical European Patients. European Prospective Cohort Stufy of the Prevalence of Frailty in Surgical Patients.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Frailty
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
Collaborators: name: Spanish Multimodal Rehabilitation Group
name: Spanish Sociey of Anesthesiology
First posted: 2019-10-25
Enrollment: 6500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who will undergo emergency or elective surgery with an intended hospital stay of more than 24 hours and any type of anesthesia.

Brief summary: European prospective one day cohort study. Analysis of the prevalence of frailty and predefined 30-day postoperative complications in adult patients undergoing emergency or elective surgery.


Eligibility criteria: Inclusion Criteria:

* Patients over the age of 18 who will undergo emergency or elective surgery with an intended hospital stay of more than 24 hours and any type of anesthesia.

Exclusion Criteria:

* Outpatient (ie. day case) surgery, obstetric analgesia or anesthesia, organ transplant surgery, cardiac surgery, neurosurgery.

Primary outcomes:
measure: The percentage of patients with frailty identified in the preoperative assessment in both elective and emergency surgery, as well as frailty's severity.
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Hospital Río Ortega
name: César Aldecoa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00882570: To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions
Official title: A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 250mg/5 ml Cefdinir (Test Formulation) and Omnicel 250mg/5 ml Powder For Oral Suspension (Reference Formulation) Each Given as a Single Oral Dose to Forty Healthy Male and/or Female Volunteers in the Fasting State
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Antibiotic
Lead sponsor: Sandoz
Sponsor class: INDUSTRY
First posted: 2009-04-16
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 56
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To demonstrate the relative bioequivalence of Cefdinir and Omnicel 250mg/5 ml fasting conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.

Primary outcomes:
measure: Bioequivalence based on AUC and Cmax
timeFrame: 10 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: SFBC Anapharm
name: Richard Larouche, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04183699: Optimizing the Number of Systematic COres During a MRI Target Biopsy
Official title: Identifying the Optimal Biopsy Scheme at MRI Target Biopsy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Suspicion of Prostate Cancer With a Positive Multiparametric Magnetic Resonance of the Prostate
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2019-12-03
Enrollment: 265
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a multicentre, paired-cohort, prospective, controlled study. The patient with a suspicion of PCa and a concomitant positive mpMRI (defined as presence of one lesion PI-RADS ≥ 3) will receive a MRI-TBx (4 target cores). During the same session, subsequently to MRI-TBx, patient will receive a systematic sampling with 6-core S-Bx followed by 14-core S-Bx, for a total of 20-core systematic cores, in addition to 4 MRI-TBx cores. Procedure will be performed by the same operator. Each single core will be stored in a dedicated cassette and sequentially numbered. We hypothesize that the proportion of csPCa (defined as prostate cancer with Gleason score ≥ 3+4) detected by 6-cores S-Bx will be no less than that detected by 20-cores S-Bx, both performed in addition to MRI-TBx. Assessing the optimal number of systematic cores to take in addition to MRI-TBx cores in men undergoing a MRI-TBx would provide a useful clinical information for every day clinical practice. Moreover, the possibility to decrease the number of systematic cores taken during a MRI-TBx, hence reducing the overall number of cores taken during a biopsy, would reduce the length of the diagnostic procedure, potentially reduce the probability of infections/sepsis and reduce the overdiagnosis of clinically insignificant PCa.


Eligibility criteria: Inclusion Criteria:

* Male patients, aged between 18 and 80 years old with suspicion of prostate cancer
* Presence of a positive mpMRI of the prostate (visible lesion PI-RADS ≥ 3)
* Serum PSA ≤ 20ng/ml
* Suspected stage ≤ T2 on rectal examination (organ confined prostate)
* Fit to undergo a prostate biopsy
* Able to understand and willing to sign a written informed consent document

Exclusion Criteria:

* Prior positive prostate biopsy
* Prior treatment of the prostate
* Prostate volume \<30 ml at mpMRI of the prostate
* More than one lesion at mpMRI of the prostate
* Contraindication to prostate biopsy

Primary outcomes:
measure: Detection rate of clinically significant prostate cancer with 6-core vs. 20-core systematic biopsy during a MRI target biopsy
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Incremental value of any additional systematic and targeted core on the detection rate of clinically significant prostate cancer during MRI target biopsy
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Milan
country: Italy
facility: IRCCS San Raffaele
Study officials:
References:
Clinical trial NCT00177099: Effects of Ligands on Human Hair Follicles Grafted Onto SCID Mice
Official title: Neurotrophic Effects of Immunophilin Ligands on Human Hair Follicles Grafted Onto Service Combined Immunodeficient (SCID) Mice
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alopecia
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 35
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if immunophilin ligands may have the potential to reverse hair loss.

Detailed description: Preliminary experiments in C57BL/6J mice showed that immunophilin ligand FK506 and its non-immunosuppressive analogs, GP11046 and GP11511 were capable of promoting telogen to anagen transition. Since GP11046 and GP11511 possess the neurotrophic properties of FK506 without its immunosuppressant capability, the neural action of these immunophilin ligands may play an important role in the hair cycle. This finding has significant clinical implications in that immunophilin ligands may have the potential to reverse alopecia. To further investigate this possibility we propose to explore the response of transplanted miniaturized scalp hair follicles to topically applied immunophilin ligands.

Eligibility criteria: Inclusion Criteria:

* Healthy men ages 18-65 with Hamilton type IV or V alopecia

Exclusion Criteria:

* Individuals who do not meet the inclusion criteria.

Primary outcomes:
measure: The average number of terminal hairs per graft will be compared between the control and the treated group.
Secondary outcomes:
measure: The number of follicles in anagen, catagen and telogen per graft will be averaged for each group. The results will be compared between the control and the treated groups.
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Marna Ericson, Ph D
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Minnesota
name: Maria Hordinsky, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03271099: Patient Navigation in Cancer Survivorship at a Safety Net Institution
Official title: Patient Navigation as Part of the Cancer Survivorship Care Plan at a Safety Net Institution
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Keywords: survivorship; navigation
Lead sponsor: Boston Medical Center
Sponsor class: OTHER
Collaborators: name: Harvard Pilgrim Health Care
First posted: 2017-09-01
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study seeks to enroll patients receiving a Survivorship Care Plan following curative therapy for cancer. Participants will be randomly assigned to receive usual care or to be followed by a Patient Navigator as part of their Survivorship Care Plan.

Detailed description: This study seeks to enroll patients receiving a Survivorship Care Plan following curative therapy for cancer. Participants will be randomly assigned to receive usual care or to be followed by a Patient Navigator as part of their Survivorship Care Plan.

Study participation for all participants will be for up to 9 months, with study visits approximately every 3 months, based on standard clinical follow-up. All participants will be administered quality of life surveys by a Clinical Research Associate at study entry, mid-study (approximately 3-6 months) and at study completion.

The following factors will be compared between arms:

* Missed/kept appointments
* Use of urgent/emergent care
* Quality of Life in relation to survivorship care
* Participants lost to care

Eligibility criteria: Inclusion Criteria:

* Stage I, II, III or IVa Cancer diagnosis (may include Solitary plasmacytoma, Diffuse Large B-Cell Lymphoma (DLBCL), ductal carcinoma in situ (DCIS) of the breast)
* Completed treatment with curative intent within the past 12 months. (May be on maintenance therapy.)

Exclusion Criteria:

* Distant Metastatic disease
* Non-curable disease
* Recurrence of disease prior to enrollment
* Require ongoing navigation from the treatment navigator
* Enrolled/active in another randomized study (Project SUPPORT)

Primary outcomes:
measure: Missed appointments
timeFrame: 9 months
Secondary outcomes:
measure: Urgent/emergent care
timeFrame: 9 months
measure: Cancer Needs Distress
timeFrame: 9 months
measure: New Survivor Survey
timeFrame: 9 months
measure: Lost to Care
timeFrame: 9 months
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Medical Center
state: Massachusetts
Study officials:
affiliation: Boston Medical Center
name: Minh Tam Truong, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03248999: Prevalence of ESBL-producing Enterobacteriaceae as Carbapenem-resistant Enterobacteriaceae in Nursing Homes.
Official title: Determination of the Prevalence of ESBL-producing Enterobacteriaceae as Carbapenem-resistant Enterobacteriaceae in Nursing Homes in Franche-Comté (France).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Drug Resistance, Bacterial
Keywords: multidrug resistance
nursing home
ESBL
CRE
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2017-08-15
Enrollment: 264
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study evaluates individual and collective factors of ESBL and CRE carriage in nursing homes.

Detailed description: Epimiological data concerning ESBL an CRE, may differ between nursing home and hospital or community but poor data are available.

Multi-drug resistant bacteria carriage is associated with individual and collective factors wich have to be defined in nursing homes.

Eligibility criteria: Inclusion Criteria:

* voluntary residents present in the institution on the study day

Exclusion Criteria:

* dement-wandering resident
* unlikely to cooperate

Primary outcomes:
measure: ESBL and CRE carriage
timeFrame: the day of the study
Secondary outcomes:
measure: patient and establishment factors associated with ESBL and CRE carriage with a questionnaire
timeFrame: the day of the study
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU Besançon
Study officials:
affiliation: CHU de Besançon
name: Céline C Bouvier-Slekovec, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01586299: NSAIDs Treatment in Children With Pleuropneumonia
Official title: The Role of Non Steroidal Anti Inflammatory Drugs in the Treatment of Pleuropneumonia in Children. a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pleuro-pneumonia
Keywords: pleuropneumonia children
non steroidal anti inflammatory drugs
pleural effusion
severe pneumonia
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2012-04-26
Enrollment: 40
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the influence of routine NSAIDs treatment for hospitalized children with pleuropneumonia in comparison with acetominophen treatment (all in conjunction with adequate antibiotic therapy).


Eligibility criteria: Inclusion Criteria:

* age less than 18 years
* admission in Schneider childrenMC of Israel, wards a/c
* clinical diagnosis of pneumonia with evidence of pleural effusion on chest X-ray
* parental informed consent
* follow-up ability after discharge

Exclusion Criteria:

* pneumonia secondary to foreign body aspiration
* immune deficiency
* chronic lung disease other than asthma (CF, CLD of prematurity, Familial Dysautonomia, etc)
* significant premorbidity (organ failure, rheumatic disease, etc)
* endotracheal/endobronchial devices including tracheostomy.
* parental refusal to participate in the study.

Primary outcomes:
measure: clinical improvement as manifested by resolution of fever and length of hospital admission.
timeFrame: participants will be followed for the duration of hospital stay, an expected average of 10 days
Secondary outcomes:
measure: clinical improvement as manifested by respiratory parameters (tachypnea, dyspnea, Fio2),and inflammatory markers.
timeFrame: participants will be followed for the duration of hospital stay, an expected average of 10 days
Other outcomes:
Locations:
city: Petah Tikva
country: Israel
facility: Schneider's medical center of Israel
Study officials:
affiliation: schneider children MC of Israel
name: havatzelet yarden-bilavsky, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04970199: Cardiovascular Protective Role of Laser Acupuncture in Systemic Lupus
Official title: Cardiovascular Protective Role of Laser Acupuncture in Systemic Lupus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: System; Lupus Erythematosus
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-07-21
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 47
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Systemic lupus erythematosus is a chronic and multisystemic autoimmune disorder which predominantly affecting women. The most common cause of death in lupus patients affected by disease for more than 5 years is cardiovascular disease due to presence of some factors as oxidative stress, pro-inflammatory cytokines , dyslipidemia, diabetes, and hypertension.

Detailed description: laser acupuncture (active or sham) for one month (3 days/week ) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser will be applied for 1 min on every acupiont) in lupus females

Eligibility criteria: Inclusion Criteria:

* lupus females
* 60 patients

Exclusion Criteria:

* pregnancy
* cardiovascular diseases
* respiratory diseases

Primary outcomes:
measure: Malondialdehyde
timeFrame: It was measured after 4 weeks
Secondary outcomes:
measure: systole
timeFrame: It was measured after 4 weeks
measure: diastole
timeFrame: It was measured after 4 weeks
measure: blood glucose
timeFrame: It was be measured after 4 weeks
measure: erythrocyte sedimentation rate (1 hour)
timeFrame: It was measured after 4 weeks
measure: erythrocyte sedimentation rate (2 hour)
timeFrame: It was measured after 4 weeks
measure: c reactive protein
timeFrame: It was measured after 4 weeks
measure: adenosine triphosphate
timeFrame: It was measured after 4 weeks
measure: Nitrate
timeFrame: It was measured after 4 weeks
measure: Glutathione
timeFrame: It was measured after 4 weeks
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Faculty of Physical Therapy Cairo University
state: Dokki
Study officials:
affiliation: Cairo University
name: Ali Ismail, lecturer
role: PRINCIPAL_INVESTIGATOR
References: